Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions

29 Jul 2014

Abstract excerpt

Decitabine (5-aza-2'-deoxycytidine, 5-azadC) is used in the treatment of Myelodysplatic syndrome (MDS) and Acute Myeloid Leukemia (AML). Its mechanism of action is thought to involve reactivation of genes implicated in differentiation and transformation, as well as induction of DNA damage by trapping DNA methyltranferases (DNMT) to DNA. We demonstrate for the first time that base excision repair (BER) recognizes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25074383
DOI: 10.1093/nar/gku638

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesionsPMID 25074383Read ↗

Treatment of human cells with 5-aza-dC induces formation of PARP1-DNA covalent adducts at genomic regions targeted by DNMT1Semantic proximity Read ↗

Epigenetic anti-cancer treatment with a stabilized carbocyclic Decitabine analogueSemantic proximity Read ↗

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Semantic proximity Read ↗

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesSemantic proximity Read ↗

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged SwordSemantic proximity Read ↗

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cellsSemantic proximity Read ↗

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.Semantic proximity Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.Semantic proximity Read ↗

A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute LeukemiaSemantic proximity Read ↗

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.